Filing Details

Accession Number:
0001209191-22-004735
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-25 14:30:20
Reporting Period:
2022-01-21
Accepted Time:
2022-01-25 14:30:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815776 Graphite Bio Inc. GRPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1253170 Srinivas Akkaraju 628 Middlefield Road
Palo Alto CA 94301
No No Yes No
1699737 Samsara Biocapital, L.p. 628 Middlefield Road
Palo Alto CA 94301
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-21 100,000 $8.99 8,011,850 No 4 P Indirect By Fund
Common Stock Acquisiton 2022-01-24 23,000 $8.70 8,034,850 No 4 P Indirect By Fund
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Fund
No 4 P Indirect By Fund
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 37,753 Indirect By Fund
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.90 to $9.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. Shares are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.67 to $8.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  4. Shares are held by 436, L.P. ("436 LP"). 436, LLC ("436 LLC") is the general partner of 436 LP and may be deemed to beneficially own the shares held by 436 LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by 436 LP and, accordingly, may be deemed to beneficially own the shares held by 436 LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.